CD-NP, a chimeric natriuretic peptide for the treatment of heart failure

Current Opinion in Investigational Drugs

Volumn 11, Issue 3, 2010, Pages 349-356

  Rose, R A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CD NP; CHIMERIC PROTEIN; CYCLIC GMP; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPNEA; FLUSHING; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TACHYCARDIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; ELAPID VENOMS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, C-TYPE; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 77649130274     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. Young JB, Abraham WT, Stevenson LW, Horton DP, Elkayam U, Bourge RC JAMA-J AM MED ASSOC 2002 287 2 1531-1540
2. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, Mukoyama M, Saito Y, Nakao K, Imura H Circulation 1991 84 4 1581-1588
3. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide Dendroaspis natriuretic peptide. Chen HH, Lainchbury JG, Burnett JC J Am Coll Cardiol 2002 40 6 1186-1191
4. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K JAMA-J MED ASSOC 2005 293 15 1900-1905
5. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Sackner-Bernstein JD, Skopicki HA, Aaronson KD Circulation 2005 111 12 1487-1491
6. Design, synthesis and unique biological actions of CD-NP: A novel CNP-like chimeric natriuretic peptide. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Circulation 2006 114 18 Suppl Abs 2166
7. Peter M. Strumph named CEO of Nile Therapeutics. Nile Therapeutics PRESS RELEASE 2007 May 31
8. Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor. Johns DG, Ao ZH, Heidrich BJ, Hunsberger GE, Graham T, Payne L, Elshourbagy N, Lu Q, Aiyar N, Douglas SA Biochem Biophys Res Commun 2007 358 1 145-149
9. Pharmacodynamic profile of a novel chimeric natriuretic peptide, CD-NP, as compared to C-Type natriuretic peptide. Lee CY, Boerrigter G, Harty GJ, Lisy O, Burnett JC AM HEART ASSOC SCIENTIFIC SESSIONS 2007 Abs 2495
10. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, Fowler MB J Am Coll Cardiol 2007 50 19 1835-1840
11. NCT00699712: Study to assess hemodynamic effects, safety and tolerability of chimeric natriuretic peptide (CD-NP) in patients with stabilized acute heart failure (AHF) (PreCONDITION). CLINICALTRIALS.GOV 2008
12. Nile Therapeutics announces dosing in second phase Ib study of CD-NP in heart failure patients. Nile Therapeutics Inc PRESS RELEASE 2008 July 30
13. Nile Therapeutics announces positive interim data from phase 2a study of CD-NP in patients with heart failure. Nile Therapeutics Inc PRESS RELEASE 2008 October 14
14. Nile Therapeutics announces positive results from phase 1b safety and pharmacodynamics study of CD-NP in patients with heart failure. Nile Therapeutics Inc PRESS RELEASE 2008 December 09
15. Nile Therapeutics, Inc. announces dosing of first patient in phase 2 study of CD-NP for the treatment of acute heart failure. Nile Therapeutics Inc PRESS RELEASE 2009 August 04
16. The design, synthesis and cardiorenal actions of a new chimeric natriuretic peptide CD-NP. Lisy O, Burnett JC J AM COLL CARDIOL 2003 41 6 Abs 860-861
17. A novel next generation natriuretic peptide: CD-NP. Lisy O, Huntley BK, McCormick DJ, Burnett JC J AM COLL CARDIOL 2007 49 9 Abs 1008-1120
18. Renal cyclic GMP stimulating actions of a novel chimeric natriuretic peptide CD-NP in isolated glomeruli: Evidence for NPR-A activation. Lee CYW, Sandberg SSM, Chen HH, Lisy O, Bunnett JC J Card Fail 2008 14 6 Abs 028
19. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC J Am Coll Cardiol 2008 52 1 60-68
20. A phase I clinical trial on a novel chimeric natriuretic peptide, CD-NP. Lee CY, Chen HH, Lisy O, Sandberg SM, Heublein DM, Burnett JC J Am Coll Cardiol 2008 51 10 Abs 1021-1212
21. Prevention of cardiorenal fibrosis and suppression of proteinuria and aldosterone activation following experimental myocardial infarction with the novel natriuretic peptide CD-NP. Martin FL, Sangaralingham SJ, McKic PM, Huntley BK, Harders GE, Chen HH, Burnett JC J Card Fail 2009 15 6 Abs 006
22. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. Lee CYW, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC J Clin Pharmacol 2009 49 6 668-673
23. Initial observations of intravenous CD-NP, chimeric natriuretic peptide, on renal functions in chronic heart failure patients. Lieu H, Goldsmith S, Neutal J, Massie B, Burnett J J Card Fail 2009 15 6 Abs 254
24. A novel designer natriuretic peptide CD-NP suppresses TGF-? 1 induced collagen type I production in human cardiac fibroblasts. Ichiki T, Huntley BK, Sangaralingham SJ, Chen HH, Burnett JC J Card Fail 2009 15 6 Abs 102
25. The new designer peptide CD-NP unloads the heart, suppresses renin and is natriuretic in vivo. Lisy O, Burnett JC J Card Fail 2003 9 5 Abs 112
26. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Lloyd-Jones D, Adams R, Carnethon M, De SG, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N et al CIRCULATION 2009 119 3 e21-e181
27. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Potter LR, Abbey-Hosch S, Dickey DM Endocr Rev 2006 27 1 47-72
28. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Schirger JA, Heublein DM, Chen HH, Lisy O, Jougasaki M, Wennberg PW, Burnett JC Mayo Clin Proc 1999 74 2 126-130
29. Action of C-type natriuretic peptide in isolated canine arteries and veins. Wei CM, Aarhus LL, Miller VM, Burnett JC Am J Physiol 1993 264 1 H71-H73
30. Bioactivity and metabolism of C-type natriuretic peptide in normal man. Hunt PJ, Richards AM, Espiner EA, Nicholls MG, Yandle TG J Clin Endocrinol Metab 1994 78 6 1428-1435
31. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, Kojima M, Kawano Y, Kangawa K Endocrinology 2003 144 6 2279-2284
32. Natriuretic peptide system in human heart failure. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, Edwards WD, Schaff HV, Burnett JC Circulation 1993 88 3 1004-1009
33. Atrial natriuretic factor receptors and signal transduction mechanisms. Anand-Srivastava MB, Trachte GJ Pharmacol Rev 1993 45 4 455-497
34. Natriuretic peptide C receptor signalling in the heart and vasculature. Rose RA, Giles WR J Physiol 2008 586 2 353-366
35. Natriuretic peptides and therapeutic applications. Lee CYW, Burnett JC Heart Fail Rev 2007 12 2 131-142
36. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M J Biol Chem 1992 267 20 13928-13932
37. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, Dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Lisy O, Lainchbury JG, Leskinen H, Burnett JC Hypertension 2001 37 4 1089-1094
38. Novel bifunctional natriuretic peptides as potential therapeutics. Dickey DM, Burnett JC, Potter LR J Biol Chem 2008 283 50 35003-35009
39. Neurohormonal profile of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide, in the normal dog. Lee CY, Boerrigter G, Harty GJ, Burnett JC J Card Fail 2007 13 6 Suppl Abbs 239
40. Clinical applications of B-type natriuretic peptides. Richards AM, Lainchbury JG, Troughton RW, Espiner EA, Nicholls MG Trends Endocrinol Metab 2004 15 4 170-174
41. Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations. Bryan PM, Xu X, Dickey DM, Chen Y, Potter LR Am J Physiol Renal Physiol 2007 292 5 F1636-F1644
42. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA J Am Coll Cardiol 2007 49 10 1071-1078
43. Differential regulation of membrane guanylyl cyclases in congestive heart failure: Natriuretic peptide receptor (NPR)-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR Endocrinology 2007 148 7 3518-3522
44. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Wei CM, Hu S, Miller VM, Burnett JC Biochem Biophys Res Commun 1994 205 1 765-771
45. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ Proc Natl Acad Sci USA 2003 100 3 1426-1431
46. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: Novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A Circulation 2004 110 10 1231-1235
47. Effects of C-type natriuretic peptide on ionic currents in mouse sinoatrial node: A role for the NPR-C receptor. Rose RA, Lomax AE, Kondo CS, Anand-Srivastava MB, Giles WR Am J Physiol Heart Circ Physiol 2004 286 5 H1970-H1977
48. The tumultuous journey of nesiritide: Past, present, and future. Burnett JC, Korinek J Circ Heart Fail 2008 1 1 6-8
49. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: Results of the second follow-up serial infusions of nesiritide (FUSION II) trial. Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R Circ Heart Fail 2008 1 1 9-16
50. -2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW et al CIRCULATION 2009 119 1977-2016
51. Current treatment options for early management in acute decompensated heart failure. Howlett JG CAN J CARDIOL 2008 24 Suppl B 9B-14B